biostudies-literatureRodriguez-Mora SInstituto de Salud Carlos IIINIH grantSpanish Ministry of Science and InnovationCoordinated Research Activities at the National Center of Microbiology2344https://www.ebi.ac.uk/biostudies/studies/S-EPMC10137176biostudies-literatureUnknown15(8)The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (<i>n</i> = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibodCancersPersistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.PMC10137176R01AI143567PID2019-110275RB-I00PI21/00877; PI22CIII/00059COV20_00679Perez-Olmeda MMurciano-Anton MATorres MMateos EPerez-Lamas LCasado-Fernandez GAlcami JGarcia-Perez JGarcia-Gutierrez VSainero MSCorona MLopez-Jimenez JRodriguez-Mora SCoiras MSanchez-Menendez CfalsePersistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (<i>n</i> = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibod2023-01-01T00:00:00Z2023 Apr2025-04-22T05:15:50.549Z2025-04-05T21:14:32.384ZS-EPMC101371763719027210.3390/cancers15082344